Literature DB >> 2033708

Complications after intravesical instillation of bacillus Calmette-Guerin: rhabdomyolysis and metastatic infection.

R W Armstrong1.   

Abstract

Two cases of adverse reaction to bacillus Calmette-Guerin (BCG) bladder instillations are reported. In both cases transient fevers and systemic symptoms developed following the instillations. After an additional instillation 1 patient had high fevers, severe myalgias and profound weakness followed by rhabdomyolysis and anuric renal failure, which required 3 weeks of hemodialysis before recovery. Extensive evaluation revealed no cause other than the BCG instillations. In the other patient a firm subcutaneous nodule gradually developed on the chest wall, which contained nonviable acid fast bacilli.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033708     DOI: 10.1016/s0022-5347(17)38596-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Chest wall abscess due to Mycobacterium bovis BCG after intravesical BCG therapy.

Authors:  Hajime Kanamori; Katsuhiko Isogami; Takashi Hatakeyama; Hiroo Saito; Kazuyoshi Shimada; Bine Uchiyama; Noboru Aso; Mitsuo Kaku
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

2.  Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.

Authors:  Christian Sänger; Andreas Busche; Gabriele Bentien; Ralf Spallek; Fatima Jonas; Andreas Böhle; Mahavir Singh; Sven Brandau
Journal:  BMC Cancer       Date:  2004-11-26       Impact factor: 4.430

Review 3.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.